124 related articles for article (PubMed ID: 7237501)
1. [A new feasibility of immune stimulation in diseases with reduced cell immunity? (author's transl)].
Pavelka K; Müller W
Cas Lek Cesk; 1981 May; 120(19):566-70. PubMed ID: 7237501
[No Abstract] [Full Text] [Related]
2. [Biological effects of leakadin].
Garin AM; Lichinitser MR; Dmitrieva NV; Rubtsov BI; Leneva NV
Vopr Onkol; 1988; 34(2):192-6. PubMed ID: 2964757
[TBL] [Abstract][Full Text] [Related]
3. [New therapeutic approaches in autoimmune diseases. The goal: selective modification of cell or antibody-mediated immunity].
Bicker U; Wieczorek L
Fortschr Med; 1987 Sep; 105(26):509-12. PubMed ID: 3666650
[No Abstract] [Full Text] [Related]
4. Three new agents for immunotherapy trials: azimexon, bestatin, and tuftsin.
Mathé G; Florentin I; Bruley-Rosset M; Goutner A; Serrou B
Recent Results Cancer Res; 1982; 80():331-3. PubMed ID: 6977171
[No Abstract] [Full Text] [Related]
5. Effect of the immunomodulant 2-cyanaziridine derivative BM 41.332 on adjuvant arthritis in the rat.
Bicker U
Arzneimittelforschung; 1982; 32(7):746-52. PubMed ID: 6889876
[TBL] [Abstract][Full Text] [Related]
6. Immunorestoration of anergic cancer patients by azimexon.
Goutner A; Nasrat F; Bonardelle D; Rameau G
Recent Results Cancer Res; 1980; 75():47-52. PubMed ID: 7232839
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of BM 12,531 (Prop. INN azimexon).
Bicker U
Recent Results Cancer Res; 1980; 75():147-52. PubMed ID: 7232826
[TBL] [Abstract][Full Text] [Related]
8. [Use of levamisole, an immune controlling agent in various clinical conditions mainly liver diseases (author's transl)].
Miyake M
Fukuoka Igaku Zasshi; 1981 Jun; 72(6):368-78. PubMed ID: 6975743
[No Abstract] [Full Text] [Related]
9. [Immunotherapy with leakadin in the combined therapy of acoustic neurinomas].
Khil'ko VA; Lantsov AA; Gorokhov AA; Starchenko AA; Komarets SA; Khlunovskiĭ AN
Vestn Otorinolaringol; 1994; (2):17-9. PubMed ID: 7855992
[TBL] [Abstract][Full Text] [Related]
10. [Natural killer (NK) activity in patients with sarcoidosis (author's transl)].
Ina Y; Yamamoto M; Takada K; Sugiura T; Morishita M; Takano K; Aoki H; Torri Y; Ichimura K; Suzuki M; Koide Y
Nihon Kyobu Shikkan Gakkai Zasshi; 1982 Feb; 20(2):189-92. PubMed ID: 7098183
[No Abstract] [Full Text] [Related]
11. Phase II trial of aziridinylbenzoquinone (AZQ) in head and neck cancer.
Forastiere AA; Crain SM; Callahan K; Van Echo D; Mattox D; Thant M; Von Hoff DD; Wiernik PH
Cancer Treat Rep; 1982 Dec; 66(12):2097-8. PubMed ID: 6892491
[No Abstract] [Full Text] [Related]
12. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory lymphoma.
McLaughlin P; Cabanillas F; Bedikian AY; Bodey GP
Cancer Treat Rep; 1983 May; 67(5):507-8. PubMed ID: 6850666
[No Abstract] [Full Text] [Related]
13. Influence of ciamexon on blood glucose and insulin requirement in newly manifested type I diabetics. Results of a pilot study.
Hogan M; Beyer J; Stuermer W; Weber P; Schrezenmeier J
Arzneimittelforschung; 1988 Aug; 38(8):1185-9. PubMed ID: 3058137
[TBL] [Abstract][Full Text] [Related]
14. Diaziquone for resistant multiple myeloma. Cancer and Leukemia Group B.
Vinciguerra V; Anderson K; McIntyre OR
Cancer Treat Rep; 1985 Mar; 69(3):331-2. PubMed ID: 3884154
[No Abstract] [Full Text] [Related]
15. [Breast cancer: a dynamic approach of cellular immunity and immunostimulation with an immunoadjuvant: P40 fraction. (author's transl)].
Santus JP; Henocq E; Bizzini B; Bazin JC; Mogenet M; Villet R; Reynier J
Pathol Biol (Paris); 1979 Sep; 27(7):395-401. PubMed ID: 388318
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.
Tilchen EJ; Fleming T; Mills G; Oishi N; Bonnett JD; Natale RB; Harker G; Coltman CA
Cancer Treat Rep; 1987 Dec; 71(12):1309-10. PubMed ID: 3690548
[No Abstract] [Full Text] [Related]
17. Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study.
Stuckey WJ; Crowley J; Baker LH; Larrimer NR; Hanson KH; Bonnet JD; White LA
Cancer Treat Rep; 1987 Nov; 71(11):1095-6. PubMed ID: 3119202
[No Abstract] [Full Text] [Related]
18. Phase II study of diaziquone in patients with advanced carcinoma of the lung.
Frytak S; Eagan RT; Creagan ET; Nichols WC
Cancer Treat Rep; 1984 Sep; 68(9):1193-4. PubMed ID: 6478455
[No Abstract] [Full Text] [Related]
19. Phase I-II diaziquone chemotherapy in brain tumors.
Madajewicz S; Spaulding M; Bhimani S; Avellanosa A; DeLos Santos R; Perry A; Zeigler P; Kirshner J
Cancer Treat Rep; 1984 Jun; 68(6):913-4. PubMed ID: 6733706
[No Abstract] [Full Text] [Related]
20. [Results of experimental and clinical studies of a new antileukemic drug: hexaphosphamide. Review of the literature and the author's own results].
Khomchenovskii EI
Haematologia (Budap); 1977; 11(1-2):115-26. PubMed ID: 352850
[No Abstract] [Full Text] [Related]
[Next] [New Search]
